News for Aprea Therapeutics, Inc. (APRE)

As of the first quarter of 2025, APRE reported a decline in its cash reserves, with cash and cash equivalents totaling $19.3 million. This marks a decrease from

Aprea (APRE) announced a decrease in its first-quarter revenue, reporting $162,463 compared to $380,569 in the previous period. Despite this decline, 2025 comme

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the o

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

**media[581369]**

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice dail

New York-based Y-mAbs Therapeutics, Inc. (YMAB) is down over 26 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. ( APRE) (”œAprea”, or the ”œCompany”), a clinical-stage biopharmaceutical c

**media[563255]**

**media[504192]**

Lexicon Appoints Scott Coiante as Chief Financial Officer

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24

After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 14.67% and 21.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities ...

On October 11, 2024, Bernd Seizinger, Director at Aprea Therapeutics Inc (APRE), purchased 10,000 shares of the company. The transaction was documented in a rec

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit